{"pub": "financialpost", "url": "https://globenewswire.com/news-release/2019/10/15/1930179/0/en/BriaCell-Announces-Closing-of-Non-Brokered-Private-Placement-of-568-444.html", "downloaded_at": "2019-10-15 23:05:13.645241+00:00", "title": "BriaCell Announces Closing of Non-Brokered Private Placement of $568,444", "language": "en", "text": "BERKELEY, Calif., and VANCOUVER, British Columbia, Oct. 15, 2019 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (\"BriaCell\" or the \"Company\") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, announces that it has closed its previously-announced non-brokered private placement (the \u201cOffering\u201d) of common shares in the capital of the Company. Under the Offering, the Company issued a total of 8,120,633 common shares at a price of C$0.07 per common share for gross proceeds of C$568,444.\n\n\n\nBriaCell directors purchased 5,714,328 common shares for aggregate proceeds of C$400,003, included in the C$568,444 total proceeds figure.\n\n\u201cI wanted to take this opportunity to thank our board members for their time, dedication, and ongoing contribution,\u201d said Dr. Bill Williams, BriaCell\u2019s President & CEO. \u201cI also wanted to thank our new and existing investors for their continued support of our mission of developing safe and effective treatment options for advanced breast cancer patients.\u201d\n\nThe Company intends to use the proceeds from the Offering to fund research and development, and for general working capital and general corporate purposes.\n\nAll securities issued under the Offering will be subject to a hold period expiring four months plus one day following the closing of the Offering. The Offering remains subject to final approval from the TSX Venture Exchange. The Company paid a total of C$1,499 cash finders\u2019 fees on subscriptions under the Offering.\n\nBriaCell\u2019s board of directors are insiders of the Company, and insider participation in the Offering is considered a \u201crelated party transaction\u201d pursuant to Multilateral Instrument 61-101 \u2013 Protection of Minority Security Holders in Special Transactions (\u201cMI 61-101\u201d). The Company is exempt from the requirements to obtain a formal valuation or minority shareholder approval in connection with the insiders\u2019 participation in the Offering in reliance of sections 5.5(a) and 5.7(1)(a) of MI 61-101.\n\nThe securities have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the \u201cU.S. Securities Act\u201d), or any U.S. state securities laws, and may not be offered or sold in the United States or to, or for the account or benefit of, United States persons absent registration or an applicable exemption from the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws. This press release shall not constitute an offer to sell or the solicitation of an offer to buy securities in the United States, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.\n\nAbout BriaCell\n\nBriaCell is an immuno-oncology focused biotechnology company developing targeted and safe approaches for the management of cancer.\n\nBriaCell is conducting a Phase I/IIa clinical trial of Bria-IMT\u2122, BriaCell\u2019s lead candidate, in a Combination Study with immune checkpoint inhibitors such as the Incyte drugs INCMGA00012 (an anti-PD-1 antibody similar to pembrolizumab [KEYTRUDA\u00ae; manufactured by Merck & Co., Inc. (NYSE: MRK)]) and epacadostat, an orally bioavailable small-molecule inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1). The combination study is listed in ClinicalTrials.gov as NCT03328026.\n\nBriaCell currently has a non-exclusive clinical trial collaboration with Incyte Corporation to evaluate the effects of combinations of novel clinical candidates. Under the agreement, Incyte and BriaCell will be evaluating novel combinations of compounds from Incyte\u2019s development portfolio with BriaCell\u2019s drug candidates in advanced breast cancer patients.\n\nBriaCell is also developing Bria-OTS\u2122, an off-the-shelf personalized immunotherapy, for advanced breast cancer. Bria-OTS\u2122 immunotherapy treatments are personalized to match the patient without the need for personalized manufacturing. Bria-OTS\u2122, which is expected to cover over 99 percent of the patient population, is designed to produce a potent and selective immune response against the cancer of each patient while eliminating the time, expense and complex manufacturing logistics associated with other personalized immunotherapies.\n\nFor additional information on BriaCell, please visit: https://briacell.com/.\n\nCautionary Note Regarding Forward-Looking Information\n\nExcept for the statements of historical fact, this news release contains \"forward-looking information\" within the meaning of the applicable Canadian securities legislation which involves known and unknown risks relevant to the Company in particular and to the biotechnology and pharmaceutical industries in general, uncertainties and other factors that may cause actual events to differ materially from current expectation. These risks are more fully described in the Company's public filings available at www.sedar.com.\n\nReaders are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.\n\nNeither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.\n\nContact Information", "description": "", "authors": ["Briacell Therapeutics Corp"], "top_image": "http://www.globenewswire.com/Attachment/LogoDisplay/557067?filename=557067.jpg&size=1", "published_at": "2019-10-15"}